Acer Therapeutics Inc (ACER)
In a report released yesterday, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on Acer Therapeutics Inc, with a price target of $51. The company’s shares closed yesterday at $21.46.
“Acer Therapeutics has submitted a New Drug Application (NDA) to the US Administration (FDA) for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS). This is a significant but expected development and advances EDSIVO closer to approval.”
According to TipRanks.com, Raja is a 1-star analyst with an average return of -6.4% and a 42.3% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Corbus Pharmaceuticals, and Tonix Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acer Therapeutics Inc with a $50.67 average price target, representing a 136.1% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $55 price target.
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Orthofix, with a price target of $61. The company’s shares closed yesterday at $56.63.
“PT to $61 We maintain our Buy rating on OFIX shares following 3Q18 results which came in slightly ahead of expectations with rev. of $111.7M (+6.6% Y/Y xFx) vs. $110.7M/$110.6M for BTIG/Street. While Spine-Fix (net of Spinal Kinetics) and Biologics continued to drag on overall growth, BioStim and Ex-Fix each benefitted from order boluses lifting results. Accounting for the one-time orders and Spinal Kinetics, we estimate organic growth between 1.0%-1.5% in 3Q18 but viewed in the context of the 2Q18 miss, on a stack basis, combined growth in 2Q18 and 3Q18 was +4.2% Y/Y reported (estimated +1.8% Y/Y organic). Mgmt. narrowed guidance for FY18 and reiterated its commitment to 100bps of adj. EBITDA margin expansion in the organic business even in the midst of restructuring disruptions to the Spine franchise.”
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 22.1% and a 60.3% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
Currently, the analyst consensus on Orthofix is a Strong Buy with an average price target of $65.33, a 15.4% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $66 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.